VOQUEZNA (vonoprazan) - (pHalcon-EoE-201)

June 23, 2026: Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) announced it has completed enrollment in its Phase 2 pHalcon-EoE-201 trial evaluating VOQUEZNA (vonoprazan) tablets as an investigational treatment for eosinophilic esophagitis (EoE) in adults. The randomized, double-blind, placebo-controlled study enrolled 95 adults with endoscopically confirmed EoE and dysphagia across 41 U.S. sites.

Trial design: Part 1 randomizes patients evenly to VOQUEZNA 20 mg once daily vs placebo for 12 weeks; patients completing Part 1 can enter Part 2, a 12-week extension in which all participants receive VOQUEZNA 20 mg once daily.

Catalyst/timing: Topline results from the double-blind 12-week treatment portion are expected in Q4 2026.

Next steps: If results are positive, Phathom expects to discuss potential future development plans with the FDA for EoE, including potential pediatric evaluation that could potentially support an extension of regulatory exclusivity. The trial is listed as NCT06851559 on ClinicalTrials.gov.